AV

Avidity Nanomedicines

2 known investors

aviditybiosciences.com ↗

Avidity Biosciences develops Antibody Oligonucleotide Conjugates (AOCs) that combine monoclonal antibody specificity with oligonucleotide precision for targeted delivery of RNA therapeutics to treat rare genetic muscle diseases. The company has three clinical-stage programs targeting myotonic dystrophy type 1, facioscapulohumeral muscular dystrophy, and Duchenne muscular dystrophy.

Investors · 2

F-

F-Prime Capital PartnersBoston

MO

Moore Venture Partners